Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Olinvacimab - PharmAbcine

Next Previous
X
Search
Drug Profile

Olinvacimab - PharmAbcine

Alternative Names: Anti-KDR mAb - PharmAbcine; Anti-VEGFR-2-mAb-PharmAbcine; SSS-23; Tanibirumab - PharmAbcine; TTAC-0001

Latest Information Update: 28 Sep 2022

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PharmAbcine
  • Developer 3SBio; PharmAbcine
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Antibody-dependent cell cytotoxicity; Vascular endothelial growth factor A inhibitors; Vascular endothelial growth factor C inhibitors; Vascular endothelial growth factor D inhibitors; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Glioblastoma; Triple negative breast cancer
  • No development reported Cancer; Choroidal neovascularisation; Solid tumours

Most Recent Events

  • 28 Sep 2022 Olinvacimab is still in phase-I clinical trial in Triple-negative-breast cancer (Metastatic disease, Combination therapy) in Australia (IV) (NCT03720431)
  • 15 Jul 2022 PharmAbcine terminates a phase II trial in Glioblastoma (Second-line therapy or greater) in USA and Australia (IV) due to subject recruitment issues and follow-up study plans (NCT03856099)
  • 28 Mar 2022 No recent reports of development identified for phase-I development in Triple-negative-breast-cancer(Combination therapy, Metastatic disease) in Australia (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top